Founded in 2020, Purespring is a pioneering London (UK)-based gene therapy company focused on transforming treatments for patients suffering from chronic kidney diseases. It is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in approximately 60% of renal diseases.

Purespring’s proprietary adeno-associated viral (AAV) gene therapy platform technology allows working copies of genes to be delivered with high efficiency and specificity to podocytes, opening up a new and highly differentiated modality of disease modifying treatments for patients afflicted by a broad range of kidney diseases. The Company has a pipeline of programmes in development including the lead asset for the treatment of IgA Nephropathy (IgAN) and other complement-mediated kidney diseases, a programme targeting nephrotic syndrome, and an undisclosed glomerular kidney disease programme. IgAN is a common, chronic kidney disease primarily affecting young adults, where one third of patients lose kidney function within five years, leaving kidney transplant or dialysis as their only options for survival.

Gilde Healthcare co-led an oversubscribed Series B round to advance two gene therapies to clinical proof of concept.